Findings in this cohort study highlighted that in APOE4 carriers compared with noncarriers, higher levels of neurodegenerative blood biomarkers were associated with a faster rate of cognitive decline in a biracial population of community-dwelling older adults without dementia. This evidence concerns the gene APOE and dementia.